Bextra Arthritis Drug Publications
The following publications on the arthritis drug Bextra has been provided by the U.S. Food and Drug Administration, public interest groups, and Weitz & Luxenberg, PC.
• Bextra Labeling: Includes documents describing the clinical pharmacology, NDC codes with respective trade names, and current product label.
• FDA Bextra Letters: These are letters from the FDA issuing warnings and safety alerts.
• FDA Bextra Warnings: These are warnings from the manufacturer and FDA signifying warnings concerning the use of the drug Bextra.
• FDA Public Comments: This section includes comments from the public about the drug Bextra.
Weitz & Luxenberg is no longer accepting Bextra cases.
see also:
Labeling
Arthritis Drug Bextra Labeling informationofficial documents on the labeling of the arthritis drug Bextra
Letters
FDA Bextra Letters - Without a Bextra recall, Bextra is still deadlyThough no Bextra recall, Bextra, these letters show, can be dangerous.
User Warnings
Bextra User Warnings: Bextra Side EffectsBextra Side Effects are deadly
